Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

UB-312 Vaccine Well Tolerated by Healthy Adults in Ongoing Trial

UB-312, an experimental vaccine targeting aggregated and toxic forms of alpha-synuclein to treat Parkinson’s disease, was generally well tolerated at multiple doses in a clinical trial in healthy adults. Study data also suggest that UB-312 prompted an immune response, as designed, against the alpha-synuclein protein. With two doses now selected…

Spine Implants May Help Clear Up Orthostatic Hypotension

Electrical implants in the spine can clear up feelings of lightheadedness upon standing — the result of a condition called orthostatic hypotension — in people with neurological disorders like Parkinson’s disease, new research shows. Orthostatic hypotension refers to a sudden drop in blood pressure when a person moves from…

Oral GT-02287 Shows Potential to Support Nerve Cell Health

Treatment with GT-02287, an experimental oral therapy for Parkinson’s disease, corrected numerous damaging abnormalities associated with Parkinson’s in cell models, according to new data shared at a recent conference. “The data we presented at the Synuclein Meeting demonstrates further encouraging disease modifying potential for patients with Parkinson’s disease who currently…

#AAN2022 – ND0612 Shows Good Safety Profile After 4+ Years

ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than four years of treatment in a Phase 2 clinical trial of Parkinson’s patients, new data show. Findings reveal that the vast majority of adverse events (side effects) reported in…

#AAN2022 – IPX-203 Gives 1.5+ Hours More ‘Good On’ Time Per Dose

Treatment with oral IPX-203, Amneal Pharmaceuticals’ investigational extended-release carbidopa-levodopa (CD/LD) formulation, reduced “off” time by about 1.5 hours a dose, on average, compared to immediate-release tablets of the medication, according to data from a Phase 3 RISE-PD clinical trial. Top-line results from RISE-PD were announced last year. Detailed…

Gamma Knife Brain Procedure May Ease Tremor

A surgery-like brain procedure called gamma knife thalamotomy may help to ease tremor in people with Parkinson’s disease, a new study highlights. The study, “Gamma Knife stereotactic radiosurgery as a treatment for essential and parkinsonian tremor: long-term experience,” was published in Neurología. Tremor is one of…